162 related articles for article (PubMed ID: 10482466)
1. 7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist.
Kondo K; Ogawa H; Yamashita H; Miyamoto H; Tanaka M; Nakaya K; Kitano K; Yamamura Y; Nakamura S; Onogawa T; Mori T; Tominaga M
Bioorg Med Chem; 1999 Aug; 7(8):1743-54. PubMed ID: 10482466
[TBL] [Abstract][Full Text] [Related]
2. Vasopressin and a nonpeptide antidiuretic hormone receptor antagonist (OPC-31260).
Burrell LM; Phillips PA; Stephenson JM; Risvanis J; Johnston CI
Blood Press; 1994 Mar; 3(1-2):137-41. PubMed ID: 8199714
[TBL] [Abstract][Full Text] [Related]
3. Novel design of nonpeptide AVP V(2) receptor agonists: structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4, 5-tetrahydro-1H-1-benzazepine as a template.
Kondo K; Ogawa H; Shinohara T; Kurimura M; Tanada Y; Kan K; Yamashita H; Nakamura S; Hirano T; Yamamura Y; Mori T; Tominaga M; Itai A
J Med Chem; 2000 Nov; 43(23):4388-97. PubMed ID: 11087564
[TBL] [Abstract][Full Text] [Related]
4. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4'-[5-(substituted methylidene)-2,3,4,5-tetrahydro-1H-1-ben zoazepine-1-carbonyl]benzanilide and 4'-[5-(substituted methyl)-2,3-dihydro-1H-1-benzoazepine-1- carbonyl]benzanilide derivatives.
Matsuhisa A; Kikuchi K; Sakamoto K; Yatsu T; Tanaka A
Chem Pharm Bull (Tokyo); 1999 Mar; 47(3):329-39. PubMed ID: 10212383
[TBL] [Abstract][Full Text] [Related]
5. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist.
Yamamura Y; Ogawa H; Yamashita H; Chihara T; Miyamoto H; Nakamura S; Onogawa T; Yamashita T; Hosokawa T; Mori T
Br J Pharmacol; 1992 Apr; 105(4):787-91. PubMed ID: 1387020
[TBL] [Abstract][Full Text] [Related]
7. Preparation of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives as novel arginine vasopressin V(2) receptor agonists.
Tsukamoto I; Koshio H; Akamatsu S; Kuramochi T; Saitoh C; Yatsu T; Yanai-Inamura H; Kitada C; Yamamoto E; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2008 Nov; 16(21):9524-35. PubMed ID: 18835174
[TBL] [Abstract][Full Text] [Related]
8. Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds.
Ogawa H; Yamashita H; Kondo K; Yamamura Y; Miyamoto H; Kan K; Kitano K; Tanaka M; Nakaya K; Nakamura S; Mori T; Tominaga M; Yabuuchi Y
J Med Chem; 1996 Aug; 39(18):3547-55. PubMed ID: 8784453
[TBL] [Abstract][Full Text] [Related]
9. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 2-phenyl-4'-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]benzanil ide derivatives.
Matsuhisa A; Tanaka A; Kikuchi K; Shimada Y; Yatsu T; Yanagisawa I
Chem Pharm Bull (Tokyo); 1997 Nov; 45(11):1870-4. PubMed ID: 9396163
[TBL] [Abstract][Full Text] [Related]
10. Effects of an orally active vasopressin V1 receptor antagonist.
Burrell LM; Phillips PA; Stephenson J; Risvanis J; Hutchins AM; Johnston CI
Clin Exp Pharmacol Physiol; 1993 May; 20(5):388-91. PubMed ID: 8391950
[TBL] [Abstract][Full Text] [Related]
11. Antidiuretic effects of a novel nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to dogs.
Nakamura S; Hirano T; Onogawa T; Itoh S; Hashimoto A; Yamamura Y; Kondo K; Mori T; Kambe T
J Pharmacol Sci; 2004 Apr; 94(4):426-33. PubMed ID: 15107583
[TBL] [Abstract][Full Text] [Related]
12. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.
Serradeil-Le Gal C; Wagnon J; Valette G; Garcia G; Pascal M; Maffrand JP; Le Fur G
Prog Brain Res; 2002; 139():197-210. PubMed ID: 12436936
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist.
Tahara A; Saito M; Sugimoto T; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
Naunyn Schmiedebergs Arch Pharmacol; 1998 Jan; 357(1):63-9. PubMed ID: 9459574
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological profile of VP-343, a novel selective vasopressin V2 receptor antagonist, in rats.
Naito A; Ohtake Y; Hasegaw H; Fukaya AY; Kurasawa T; Naito K; Matsukawa H; Oguma T; Ezure Y; Tsuriya Y; Tanaka H; Koike K; Shigenobu K
Biol Pharm Bull; 2000 Feb; 23(2):182-9. PubMed ID: 10706381
[TBL] [Abstract][Full Text] [Related]
15. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
Serradeil-Le Gal C; Lacour C; Valette G; Garcia G; Foulon L; Galindo G; Bankir L; Pouzet B; Guillon G; Barberis C; Chicot D; Jard S; Vilain P; Garcia C; Marty E; Raufaste D; Brossard G; Nisato D; Maffrand JP; Le Fur G
J Clin Invest; 1996 Dec; 98(12):2729-38. PubMed ID: 8981918
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a novel non-peptide vasopressin V1 receptor antagonist (OPC-21268) in the rat.
Burrell LM; Phillips PA; Stephenson J; Risvanis J; Hutchins AM; Johnston CI
J Endocrinol; 1993 Aug; 138(2):259-66. PubMed ID: 8228734
[TBL] [Abstract][Full Text] [Related]
17. Antidiuretic effects of a nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to rats.
Nakamura S; Hirano T; Tsujimae K; Aoyama M; Kondo K; Yamamura Y; Mori T; Tominaga M
J Pharmacol Exp Ther; 2000 Dec; 295(3):1005-11. PubMed ID: 11082435
[TBL] [Abstract][Full Text] [Related]
18. Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors.
Tahara A; Tsukada J; Tomura Y; Kusayama T; Wada K; Ishii N; Taniguchi N; Suzuki T; Yatsu T; Uchida W; Shibasaki M
Pharmacol Res; 2005 Mar; 51(3):275-81. PubMed ID: 15661579
[TBL] [Abstract][Full Text] [Related]
19. (+/-)-3-[4'-(N,N-dimethylamino)cinnamyl]benzazepine analogs: novel dopamine D1 receptor antagonists.
Shah JH; Kline RH; Geter-Douglass B; Izenwasser S; Witkin JM; Newman AH
J Med Chem; 1996 Aug; 39(17):3423-8. PubMed ID: 8765528
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists.
Tsukamoto I; Koshio H; Kuramochi T; Saitoh C; Yanai-Inamura H; Kitada-Nozawa C; Yamamoto E; Yatsu T; Shimada Y; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2009 Apr; 17(8):3130-41. PubMed ID: 19321349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
